Ansbert Gadicke News Today

/PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics...

NOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 12, 2023 AND MANAGEMENT INFORMATION CIRCULAR JUNE 13, 2023 ... | June 20, 2023

Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact Reunion Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash ... | June 1, 2023

ReNAgade Therapeutics has announced a $300 million Series A financing round led by MPM BioImpact and F2 Ventures.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

AlloVir , a late-clinical stage allogeneic T cell immunotherapy company, today announced the appointment of Derek Adams, Ph.D., to its Board of Directors, effective March 1, 2023. Dr. Adams brings... | February 23, 2023

CAMBRIDGE, Mass., Nov. 02, 2022 -- Cullinan Oncology, Inc.  , a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, today announced that David P.... | November 2, 2022

/PRNewswire/ -- Orna Therapeutics, a biotechnology company pioneering a new class of fully engineered circular RNA therapies (oRNA), today announced the...

The first year of the covid-19 pandemic fueled a frenzy for biotechnology stocks. Now, with vaccines in millions of arms and the omicron variant on the wane, there are signs investors are ready to move on.

While an appetite for the shares of vaccine makers and drug companies remain, inflows into health care funds have slowed to more modest figures.